CLTC

Overview

CLTC (clathrin heavy chain) is well established as a fusion partner in various hematologic malignancies. In renal cell carcinoma, a novel CLTC-TFEB fusion has been identified in translocation RCC, expanding the spectrum of TFEB-driven tumors beyond classical chromosomal translocations.

Alterations observed in the corpus

• CLTC-TFEB fusion identified as novel in translocation RCC (sample 8432T, reclassified tRCC); encodes an in-frame fusion preserving the TFEB bHLH domain PMID:25401301

Cancer types (linked)

• TRCC: CLTC-TFEB fusion places this case in the MiTF-high tRCC subgroup; the case was reclassified as tRCC based on molecular findings PMID:25401301

Co-occurrence and mutual exclusivity

• CLTC-TFEB fusion is part of the broader MiTF-high subtype alongside ASPSCR1-TFE3, ACTG1-MITF fusions and TFEB focal amplification PMID:25401301

Therapeutic relevance

• MiTF-high tumors including CLTC-TFEB fusion tRCC may benefit from MET inhibitors (downstream target) and BIRC7-directed therapies PMID:25401301

Open questions

• Whether CLTC-TFEB differs functionally from classical t(6;11) TFEB translocations remains uncharacterized PMID:25401301

Sources

• PMID:25401301

This page was processed by entity-page-writer on 2026-05-11.